Anika Therapeutics (NASDAQ: ANIK) and Vericel Corporation (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
This is a breakdown of current ratings and target prices for Anika Therapeutics and Vericel Corporation, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Anika Therapeutics currently has a consensus price target of $57.00, suggesting a potential upside of 5.38%. Vericel Corporation has a consensus price target of $6.33, suggesting a potential upside of 43.94%. Given Vericel Corporation’s higher possible upside, analysts clearly believe Vericel Corporation is more favorable than Anika Therapeutics.
Earnings and Valuation
This table compares Anika Therapeutics and Vericel Corporation’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Anika Therapeutics||$111.36 million||7.12||$56.02 million||$2.13||25.39|
|Vericel Corporation||$53.77 million||2.69||-$20.03 million||($1.10)||-4.00|
Anika Therapeutics has higher revenue and earnings than Vericel Corporation. Vericel Corporation is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Anika Therapeutics and Vericel Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Anika Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Vericel Corporation has a beta of 3.16, meaning that its share price is 216% more volatile than the S&P 500.
Insider & Institutional Ownership
84.3% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of Vericel Corporation shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by insiders. Comparatively, 3.3% of Vericel Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Anika Therapeutics beats Vericel Corporation on 9 of the 12 factors compared between the two stocks.
About Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.